128 related articles for article (PubMed ID: 10698557)
1. A phosphate binding assay for sevelamer hydrochloride by ion chromatography.
Mazzeo JR; Peters RM; Hanus MR; Chen X; Norton KA
J Pharm Biomed Anal; 1999 May; 19(6):911-5. PubMed ID: 10698557
[TBL] [Abstract][Full Text] [Related]
2. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.
Swearingen RA; Chen X; Petersen JS; Riley KS; Wang D; Zhorov E
J Pharm Biomed Anal; 2002 Jun; 29(1-2):195-201. PubMed ID: 12062678
[TBL] [Abstract][Full Text] [Related]
3. Determination of the binding parameter constants of Renagel capsules and tablets at pH 7 by high performance capillary electrophoresis.
Swearingen RA; Zhorov E; Cohen A; Sybertz T; Barry EF
J Pharm Biomed Anal; 2004 Jun; 35(4):753-60. PubMed ID: 15193719
[TBL] [Abstract][Full Text] [Related]
4. Kinetic and thermodynamic evaluation of phosphate ions binding onto sevelamer hydrochloride.
Elsiddig R; Hughes H; Owens E; O' Reilly NJ; O'Grady D; McLoughlin P
Int J Pharm; 2014 Oct; 474(1-2):25-32. PubMed ID: 25102115
[TBL] [Abstract][Full Text] [Related]
5. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
Burke SK; Slatopolsky EA; Goldberg DI
Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
[TBL] [Abstract][Full Text] [Related]
6. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
Autissier V; Damment SJ; Henderson RA
J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
[TBL] [Abstract][Full Text] [Related]
7. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics.
Burke S; Amin N; Incerti C; Plone M; Watson N
J Clin Pharmacol; 2001 Feb; 41(2):193-8. PubMed ID: 11210401
[TBL] [Abstract][Full Text] [Related]
9. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
Goldberg DI; Dillon MA; Slatopolsky EA; Garrett B; Gray JR; Marbury T; Weinberg M; Wombolt D; Burke SK
Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
[TBL] [Abstract][Full Text] [Related]
10. Novel dosage forms and regimens for sevelamer-based phosphate binders.
Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
[TBL] [Abstract][Full Text] [Related]
11. Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers.
Burke SK; Amin NS; Incerti C; Plone MA; Lee JW
J Clin Pharmacol; 2001 Feb; 41(2):199-205. PubMed ID: 11210402
[TBL] [Abstract][Full Text] [Related]
12. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
Rosenbaum DP; Holmes-Farley SR; Mandeville WH; Pitruzzello M; Goldberg DI
Nephrol Dial Transplant; 1997 May; 12(5):961-4. PubMed ID: 9175050
[TBL] [Abstract][Full Text] [Related]
13. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
Taniguchi K; Kakuta H
Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of rapid ion-chromatographic method with conductivity detection for trace level determination of allylamine in sevelamer drug substances.
Karthikeyan K; Shanmugasundaram P; Ramadhas R; Pillai KC
J Pharm Biomed Anal; 2011 Jan; 54(1):203-7. PubMed ID: 20724094
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling studies of the binding characteristics of phosphates to sevelamer hydrochloride--assessing a novel technique to reduce phosphates contamination.
Parker R; Odukale AA; Fisher D; Batich C; Ross E; Edwards J
Int J Environ Res Public Health; 2006 Jun; 3(2):202-8. PubMed ID: 16823094
[TBL] [Abstract][Full Text] [Related]
16. Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1α-hydroxy cholecalciferol.
Bobeck EA; Meyer KM; Helvig C; Petkovich M; Cook ME
J Ren Nutr; 2013 Jan; 23(1):21-7. PubMed ID: 22406121
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
Bleyer AJ; Burke SK; Dillon M; Garrett B; Kant KS; Lynch D; Rahman SN; Schoenfeld P; Teitelbaum I; Zeig S; Slatopolsky E
Am J Kidney Dis; 1999 Apr; 33(4):694-701. PubMed ID: 10196011
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study.
Alam S; Hussain A; Daiwajna R; Tan J
Singapore Med J; 2013 May; 54(5):263-6. PubMed ID: 23716151
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
